NYSE:ENOV Enovis (ENOV) Stock Price, News & Analysis $37.74 -1.14 (-2.94%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$37.76 +0.02 (+0.06%) As of 03/28/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enovis Stock (NYSE:ENOV) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enovis alerts:Sign Up Key Stats Today's Range$37.39▼$38.5350-Day Range$35.55▼$47.9752-Week Range$35.14▼$62.79Volume479,654 shsAverage Volume706,157 shsMarket Capitalization$2.15 billionP/E RatioN/ADividend YieldN/APrice Target$58.50Consensus RatingModerate Buy Company OverviewEnovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.Read More… Remove Ads Enovis Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreENOV MarketRank™: Enovis scored higher than 68% of companies evaluated by MarketBeat, and ranked 331st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingEnovis has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageEnovis has only been the subject of 1 research reports in the past 90 days.Read more about Enovis' stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth14.34% Earnings GrowthEarnings for Enovis are expected to grow by 14.34% in the coming year, from $2.79 to $3.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enovis is -17.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enovis is -17.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnovis has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Enovis' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.38% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Enovis has recently decreased by 5.41%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnovis does not currently pay a dividend.Dividend GrowthEnovis does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted9.38% of the float of Enovis has been sold short.Short Interest Ratio / Days to CoverEnovis has a short interest ratio ("days to cover") of 5.5.Change versus previous monthShort interest in Enovis has recently decreased by 5.41%, indicating that investor sentiment is improving significantly. News and Social Media3.5 / 5News Sentiment1.26 News SentimentEnovis has a news sentiment score of 1.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Enovis this week, compared to 5 articles on an average week.Search Interest1 people have searched for ENOV on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Enovis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Enovis insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Enovis is held by insiders.Percentage Held by Institutions98.45% of the stock of Enovis is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enovis' insider trading history. Receive ENOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enovis and its competitors with MarketBeat's FREE daily newsletter. Email Address ENOV Stock News HeadlinesEnovis Showcases Innovative Foot and Ankle Solutions at ACFAS ConferenceMarch 27 at 4:45 PM | msn.comEnovis™ to Exhibit Extensive Range of Foot & Ankle Solutions at ACFAS 2025March 25, 2025 | globenewswire.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. March 30, 2025 | Paradigm Press (Ad)Enovis to Participate in Upcoming Investor ConferencesMarch 5, 2025 | globenewswire.comEnovis Continues To Languish Despite Decent Financial ResultsFebruary 28, 2025 | seekingalpha.comEnovis Corporation Reports Strong Growth Amid ChallengesFebruary 28, 2025 | msn.comQ4 2024 Enovis Corp Earnings CallFebruary 27, 2025 | finance.yahoo.comEnovis CEO Matt Trerotola Announces Retirement, Leadership Transition UnderwayFebruary 27, 2025 | msn.comSee More Headlines ENOV Stock Analysis - Frequently Asked Questions How have ENOV shares performed this year? Enovis' stock was trading at $43.88 on January 1st, 2025. Since then, ENOV stock has decreased by 14.0% and is now trading at $37.7380. View the best growth stocks for 2025 here. How were Enovis' earnings last quarter? Enovis Co. (NYSE:ENOV) announced its quarterly earnings data on Wednesday, February, 26th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.92 by $0.06. The firm had revenue of $560.98 million for the quarter, compared to the consensus estimate of $555.14 million. Enovis had a negative net margin of 5.95% and a positive trailing twelve-month return on equity of 4.39%. Who are Enovis' major shareholders? Top institutional investors of Enovis include T. Rowe Price Investment Management Inc. (10.84%), Vanguard Group Inc. (9.65%), Dimensional Fund Advisors LP (5.10%) and Diamond Hill Capital Management Inc. (4.91%). Insiders that own company stock include Matthew L Trerotola, Daniel A Pryor, Brady Shirley, Christopher M Hix, A Clayton Perfall, Phillip Benjamin (Ben) Berry, Patricia A Lang, Bradley J Tandy, Rajiv Vinnakota and John Kleckner. View institutional ownership trends. How do I buy shares of Enovis? Shares of ENOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enovis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enovis investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings2/26/2025Today3/30/2025Next Earnings (Estimated)5/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical appliances & supplies Sub-IndustryMedical Equipment Current SymbolNYSE:ENOV CIK1420800 Webwww.enovis.com Phone302-252-9160Fax301-323-9001Employees6,800Year FoundedN/APrice Target and Rating Average Stock Price Target$58.50 High Stock Price Target$64.00 Low Stock Price Target$50.00 Potential Upside/Downside+55.0%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($14.29) Trailing P/E RatioN/A Forward P/E Ratio13.53 P/E GrowthN/ANet Income$-33,260,000.00 Net Margins-5.95% Pretax Margin-7.07% Return on Equity4.39% Return on Assets2.80% Debt Debt-to-Equity Ratio0.40 Current Ratio2.27 Quick Ratio1.12 Sales & Book Value Annual Sales$2.11 billion Price / Sales1.02 Cash Flow$5.50 per share Price / Cash Flow6.86 Book Value$62.66 per share Price / Book0.60Miscellaneous Outstanding Shares56,963,000Free Float55,494,000Market Cap$2.15 billion OptionableOptionable Beta2.05 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NYSE:ENOV) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enovis Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enovis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.